Sangamo Therapeutics (SGMO) Stock Forecast, Price Target & Predictions
SGMO Stock Forecast
Sangamo Therapeutics stock forecast is as follows: an average price target of $12.00 (represents a 1314.43% upside from SGMO’s last price of $0.85) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
SGMO Price Target
The average price target for Sangamo Therapeutics (SGMO) is $12.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $5.00. This represents a potential 1314.43% upside from SGMO's last price of $0.85.
SGMO Analyst Ratings
According to 3 Wall Street analysts, Sangamo Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for SGMO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Sangamo Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 13, 2022 | Andreas Argyrides | Wedbush | $5.00 | $3.76 | 32.98% | 489.34% |
| Apr 05, 2022 | Nicole Germino | Truist Financial | $19.00 | $6.15 | 208.94% | 2139.51% |
The latest Sangamo Therapeutics stock forecast, released on Jun 13, 2022 by Andreas Argyrides from Wedbush, set a price target of $5.00, which represents a 32.98% increase from the stock price at the time of the forecast ($3.76), and a 489.34% increase from SGMO last price ($0.85).
Sangamo Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.85 | $0.85 | $0.85 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Sangamo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sangamo Therapeutics's last price of $0.85. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 15, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 15, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Mar 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jan 19, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Jan 19, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Nov 03, 2023 | RBC Capital | - | Sector Perform | Downgrade |
| Feb 27, 2023 | Wedbush | - | Outperform | Upgrade |
| Jan 04, 2023 | Wells Fargo | Overweight | Overweight | Hold |
Sangamo Therapeutics's last stock rating was published by RBC Capital on May 15, 2024. The company gave SGMO a "Sector Perform" rating, the same as its previous rate.
Sangamo Therapeutics Financial Forecast
Sangamo Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $2.04M | $9.40M | $6.83M | $157.96M | $27.23M | $26.46M | $29.38M | $28.23M | $27.99M | $28.56M | $27.87M | $26.28M | $25.80M | $57.76M | $21.55M | $13.08M | $54.85M | $21.96M |
| Avg Forecast | $526.94K | $506.67K | $487.19K | $468.45K | $39.25M | $12.75M | $12.75M | $12.25M | $16.98M | $20.92M | $6.88M | $6.36M | $8.11M | $9.36M | $16.75M | $24.07M | $26.86M | $26.59M | $24.63M | $27.29M | $26.82M | $25.96M | $26.53M | $28.49M | $31.42M | $26.55M | $102.71M | $22.74M | $15.54M | $12.16M |
| High Forecast | $526.94K | $506.67K | $487.19K | $468.45K | $39.25M | $12.75M | $12.75M | $12.25M | $16.98M | $31.51M | $6.88M | $6.36M | $14.87M | $9.36M | $16.75M | $24.07M | $26.86M | $26.59M | $24.63M | $27.29M | $26.82M | $25.96M | $26.53M | $28.49M | $31.42M | $26.55M | $102.71M | $22.74M | $15.54M | $12.16M |
| Low Forecast | $526.94K | $506.67K | $487.19K | $468.45K | $39.25M | $12.75M | $12.75M | $12.25M | $16.98M | $10.32M | $6.88M | $6.36M | $3.08M | $9.36M | $16.75M | $24.07M | $26.86M | $26.59M | $24.63M | $27.29M | $26.82M | $25.96M | $26.53M | $28.49M | $31.42M | $26.55M | $102.71M | $22.74M | $15.54M | $12.16M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.25% | 1.00% | 0.41% | 6.56% | 1.01% | 1.00% | 1.19% | 1.03% | 1.04% | 1.10% | 1.05% | 0.92% | 0.82% | 2.18% | 0.21% | 0.58% | 3.53% | 1.81% |
Sangamo Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $6.36M, with a low forecast of $6.36M, and a high forecast of $6.36M. SGMO's average Quarter revenue forecast represents a 211.32% increase compared to the company's last Quarter revenue of $2.04M (Dec 23).
Sangamo Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-59.38M | $-106.41M | $-123.57M | $140.76M | $-55.39M | $-54.89M | $-40.73M | $-40.32M | $-32.70M | $-43.01M | $-42.86M | $-41.77M | $-36.83M | $1.97M | $-32.70M | $-39.72M | $11.42M | $-26.15M |
| Avg Forecast | $-476.63K | $-458.30K | $-440.67K | $-423.73K | $-35.50M | $-11.53M | $-11.53M | $-11.08M | $-15.36M | $-18.92M | $-6.23M | $-49.85M | $-7.33M | $-8.47M | $-15.15M | $-45.32M | $-24.29M | $-48.70M | $-22.28M | $-41.20M | $-24.26M | $-23.48M | $-24.00M | $-37.45M | $-28.42M | $-24.02M | $-92.90M | $-28.76M | $-14.06M | $-11.00M |
| High Forecast | $-476.63K | $-458.30K | $-440.67K | $-423.73K | $-35.50M | $-11.53M | $-11.53M | $-11.08M | $-15.36M | $-9.34M | $-6.23M | $-39.88M | $-2.78M | $-8.47M | $-15.15M | $-36.25M | $-24.29M | $-38.96M | $-22.28M | $-32.96M | $-24.26M | $-23.48M | $-24.00M | $-29.96M | $-28.42M | $-24.02M | $-92.90M | $-23.01M | $-14.06M | $-11.00M |
| Low Forecast | $-476.63K | $-458.30K | $-440.67K | $-423.73K | $-35.50M | $-11.53M | $-11.53M | $-11.08M | $-15.36M | $-28.50M | $-6.23M | $-59.82M | $-13.45M | $-8.47M | $-15.15M | $-54.38M | $-24.29M | $-58.44M | $-22.28M | $-49.44M | $-24.26M | $-23.48M | $-24.00M | $-44.94M | $-28.42M | $-24.02M | $-92.90M | $-34.51M | $-14.06M | $-11.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 8.10% | 12.57% | 8.16% | -3.11% | 2.28% | 1.13% | 1.83% | 0.98% | 1.35% | 1.83% | 1.79% | 1.12% | 1.30% | -0.08% | 0.35% | 1.38% | -0.81% | 2.38% |
3 analysts predict SGMO's average Quarter EBITDA for Jun 23 to be $-15.15M, with a high of $-15.15M and a low of $-15.15M. This is -110.76% lower than Sangamo Therapeutics's previous annual EBITDA (Mar 23) of $140.76M.
Sangamo Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-60.30M | $-104.16M | $-114.51M | $21.13M | $-51.97M | $-53.16M | $-43.17M | $-43.98M | $-37.50M | $-47.69M | $-47.17M | $-45.93M | $-40.60M | $-1.55M | $-35.93M | $-42.91M | $4.55M | $-27.31M |
| Avg Forecast | $-33.26M | $-34.65M | $-33.47M | $-34.85M | $-11.42M | $-20.29M | $-19.65M | $-18.99M | $-10.23M | $-3.06M | $-29.92M | $-54.81M | $-52.28M | $-65.03M | $-68.60M | $-49.83M | $-73.42M | $-54.00M | $-71.94M | $-45.30M | $-70.45M | $-68.71M | $-63.85M | $-41.18M | $-43.39M | $-49.35M | $22.18M | $-31.07M | $-66.54M | $-69.60M |
| High Forecast | $-33.26M | $-34.65M | $-33.47M | $-34.85M | $-11.42M | $-20.29M | $-19.65M | $-18.99M | $-10.23M | $873.36K | $-29.92M | $-43.85M | $-37.64M | $-65.03M | $-68.60M | $-39.86M | $-73.42M | $-43.20M | $-71.94M | $-36.24M | $-70.45M | $-68.71M | $-63.85M | $-32.95M | $-43.39M | $-49.35M | $22.18M | $-24.86M | $-66.54M | $-69.60M |
| Low Forecast | $-33.26M | $-34.65M | $-33.47M | $-34.85M | $-11.42M | $-20.29M | $-19.65M | $-18.99M | $-10.23M | $-6.11M | $-29.92M | $-65.77M | $-64.82M | $-65.03M | $-68.60M | $-59.80M | $-73.42M | $-64.80M | $-71.94M | $-54.36M | $-70.45M | $-68.71M | $-63.85M | $-49.42M | $-43.39M | $-49.35M | $22.18M | $-37.29M | $-66.54M | $-69.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.60% | 1.67% | -0.42% | 0.71% | 0.98% | 0.60% | 0.97% | 0.53% | 0.69% | 0.74% | 1.12% | 0.94% | 0.03% | -1.62% | 1.38% | -0.07% | 0.39% |
Sangamo Therapeutics's average Quarter net income forecast for Jun 23 is $-68.60M, with a range of $-68.60M to $-68.60M. SGMO's average Quarter net income forecast represents a -424.62% decrease compared to the company's last Quarter net income of $21.13M (Mar 23).
Sangamo Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $10.22M | $13.92M | $16.01M | $18.14M | $16.44M | $16.24M | $15.09M | $14.91M | $16.08M | $14.50M | $16.49M | $16.15M | $16.87M | $16.18M | $17.93M | $16.12M | $15.05M | $14.92M |
| Avg Forecast | $265.48K | $255.27K | $245.46K | $236.02K | $19.78M | $6.42M | $6.42M | $6.17M | $8.56M | $10.54M | $3.47M | $3.20M | $4.08M | $4.72M | $8.44M | $17.52M | $13.53M | $16.42M | $12.41M | $15.93M | $13.51M | $13.08M | $13.37M | $14.48M | $15.83M | $13.38M | $51.75M | $11.67M | $7.83M | $6.13M |
| High Forecast | $265.48K | $255.27K | $245.46K | $236.02K | $19.78M | $6.42M | $6.42M | $6.17M | $8.56M | $15.88M | $3.47M | $3.20M | $7.49M | $4.72M | $8.44M | $21.02M | $13.53M | $19.70M | $12.41M | $19.11M | $13.51M | $13.08M | $13.37M | $17.37M | $15.83M | $13.38M | $51.75M | $14.01M | $7.83M | $6.13M |
| Low Forecast | $265.48K | $255.27K | $245.46K | $236.02K | $19.78M | $6.42M | $6.42M | $6.17M | $8.56M | $5.20M | $3.47M | $3.20M | $1.55M | $4.72M | $8.44M | $14.01M | $13.53M | $13.14M | $12.41M | $12.74M | $13.51M | $13.08M | $13.37M | $11.58M | $15.83M | $13.38M | $51.75M | $9.34M | $7.83M | $6.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.50% | 2.95% | 1.90% | 1.04% | 1.22% | 0.99% | 1.22% | 0.94% | 1.19% | 1.11% | 1.23% | 1.12% | 1.07% | 1.21% | 0.35% | 1.38% | 1.92% | 2.43% |
Sangamo Therapeutics's average Quarter SG&A projection for Mar 24 is $3.20M, based on 3 Wall Street analysts, with a range of $3.20M to $3.20M. The forecast indicates a -68.65% fall compared to SGMO last annual SG&A of $10.22M (Dec 23).
Sangamo Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.59 | $-0.66 | $0.13 | $-0.32 | $-0.34 | $-0.29 | $-0.30 | $-0.26 | $-0.33 | $-0.33 | $-0.32 | $-0.29 | $-0.01 | $-0.26 | $-0.37 | $0.04 | $-0.24 |
| Avg Forecast | $-0.16 | $-0.17 | $-0.16 | $-0.17 | $-0.06 | $-0.10 | $-0.10 | $-0.09 | $-0.05 | $-0.01 | $-0.15 | $-0.21 | $-0.26 | $-0.32 | $-0.34 | $-0.33 | $-0.36 | $-0.36 | $-0.35 | $-0.31 | $-0.35 | $-0.34 | $-0.31 | $-0.29 | $-0.21 | $-0.24 | $0.11 | $-0.28 | $-0.33 | $-0.34 |
| High Forecast | $-0.16 | $-0.17 | $-0.16 | $-0.17 | $-0.06 | $-0.10 | $-0.10 | $-0.09 | $-0.05 | - | $-0.15 | $-0.21 | $-0.18 | $-0.32 | $-0.34 | $-0.33 | $-0.36 | $-0.36 | $-0.35 | $-0.31 | $-0.35 | $-0.34 | $-0.31 | $-0.29 | $-0.21 | $-0.24 | $0.11 | $-0.28 | $-0.33 | $-0.34 |
| Low Forecast | $-0.16 | $-0.17 | $-0.16 | $-0.17 | $-0.06 | $-0.10 | $-0.10 | $-0.09 | $-0.05 | $-0.03 | $-0.15 | $-0.21 | $-0.32 | $-0.32 | $-0.34 | $-0.33 | $-0.36 | $-0.36 | $-0.35 | $-0.31 | $-0.35 | $-0.34 | $-0.31 | $-0.29 | $-0.21 | $-0.24 | $0.11 | $-0.28 | $-0.33 | $-0.34 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.33% | 1.85% | 1.96% | -0.40% | 0.89% | 0.96% | 0.82% | 0.96% | 0.75% | 0.98% | 1.05% | 1.09% | 1.36% | 0.04% | -2.39% | 1.34% | -0.12% | 0.70% |
According to 3 Wall Street analysts, Sangamo Therapeutics's projected average Quarter EPS for Jun 23 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -358.75% decrease compared to SGMO previous annual EPS of $0.13 (Mar 23).
Sangamo Therapeutics Peer Comparison by Price Target
SGMO Forecast FAQ
Is Sangamo Therapeutics a good buy?
No, according to 3 Wall Street analysts, Sangamo Therapeutics (SGMO) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of SGMO's total ratings.
What is SGMO's price target?
Sangamo Therapeutics (SGMO) average price target is $12 with a range of $5 to $19, implying a 1314.43% from its last price of $0.848. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sangamo Therapeutics stock go up soon?
According to Wall Street analysts' prediction for SGMO stock, the company can go up by 1314.43% (from the last price of $0.848 to the average price target of $12), up by 2139.51% based on the highest stock price target, and up by 489.34% based on the lowest stock price target.
Can Sangamo Therapeutics stock reach $1?
SGMO's average twelve months analyst stock price target of $12 supports the claim that Sangamo Therapeutics can reach $1 in the near future.
What are Sangamo Therapeutics's analysts' financial forecasts?
Sangamo Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $77M (high $77M, low $77M), average EBITDA is $-69.648M (high $-69.648M, low $-69.648M), average net income is $-70.355M (high $-70.355M, low $-70.355M), average SG&A $38.79M (high $38.79M, low $38.79M), and average EPS is $-0.345 (high $-0.345, low $-0.345). SGMO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.99M (high $1.99M, low $1.99M), average EBITDA is $-1.799M (high $-1.799M, low $-1.799M), average net income is $-136M (high $-136M, low $-136M), average SG&A $1M (high $1M, low $1M), and average EPS is $-0.668 (high $-0.668, low $-0.668).
Did the SGMO's actual financial results beat the analysts' financial forecasts?
Based on Sangamo Therapeutics's last annual report (Dec 2023), the company's revenue was $176.23M, beating the average analysts forecast of $58.28M by 202.39%. Apple's EBITDA was $-274M, beating the average prediction of $-76.265M by 259.28%. The company's net income was $-258M, beating the average estimation of $-236M by 9.37%. Apple's SG&A was $61.17M, beating the average forecast of $34.76M by 75.99%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.24 by 19.38%. In terms of the last quarterly report (Dec 2023), Sangamo Therapeutics's revenue was $2.04M, missing the average analysts' forecast of $8.1M by -74.81%. The company's EBITDA was $-59.381M, beating the average prediction of $-7.331M by 709.98%. Sangamo Therapeutics's net income was $-60.296M, beating the average estimation of $-52.277M by 15.34%. The company's SG&A was $10.22M, beating the average forecast of $4.08M by 150.20%. Lastly, the company's EPS was $-0.34, beating the average prediction of $-0.256 by 32.64%